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Alzheimer’s disease (AD), Parkinson’s disease (PD),
and motor neuron disease are the most common of the
neurodegenerative disorders beginning in middle to late
life. Each condition is believed to be complex in etiology,
the combined result of environmental and genetic determi-
nants, but few etiologic factors are known. In each disor-
der, degeneration affects selected neuronal populations,
resulting in characteristic clinical syndromes. Symptom
onset is gradual, with progressive worsening over years.
Protein aggregation is a unifying pathologic feature,
although the specific proteins (e.g., tau, alpha-synuclein,ccess article under the CC BY-NC-ND license (http://
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[1]. Diagnosis is typically after the fifth decade, but the un-
derlying disease process is thought to begin years before
diagnosis. The number and proportion of elderly in the
U.S. population is growing rapidly, including aging veter-
ans, with attendant increases in the economic and societal
costs of late-life neurodegenerative disorders. Investiga-
tion of causes and preventive interventions are thus
increasingly relevant. Recent epidemiological and labora-
tory studies suggest that exposures years or decades before
diagnosis can trigger the processes that ultimately result in
a neurodegenerative disease. If this is correct, preventive
measures may be needed in midlife or earlier.
In this article, we will focus on putative risk factors rele-
vant to military service. Even though active-duty service
personnel are not as overtly affected, the unknown prodro-
mal phase of these neurodegenerative conditions suggests
that active duty personnel may suffer decrements in physical
and cognitive performance, particularly when exposed to
known risk factors associated with development of theseimer’s Association.
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personnel or veterans, most of the work discussed will be
based on observations in civilian populations.Fig. 1. MPP1 and paraquat.2. Alzheimer’s disease
AD is the most common cause of dementia in late life.
Recent prevalence estimates suggest that dementia affects
about 6%of theNorthAmerican population 60years and older
and 30% of those 85 years and older [2]. Information from the
Department ofVeteran’s Affairs (VA) suggests that: “The esti-
mated number of U.S. Department of Veterans Affairs (VA)
patients with all types of dementia (prevalence) in 2014 is
262,899 and ranges from a low of 135,216 to a high of
390,567. The low and high values are estimated based on the
lower and upper bounds of the 95% confidence interval of
prevalence rates reported in the research. These numbers are
based on national prevalence rates for all types of dementia,
applied to the VA patient population estimates. The estimated
number of VA patients with Alzheimer’s type dementia (prev-
alence) in 2014 is 166,872 and ranges froma lowof65,663 to a
high of 269,566. The low and high values are estimated based
on the lower and upper bounds of the 95% confidence interval
of prevalence rates reported in the research. These numbers are
based on national prevalence rates for Alzheimer’s dementia,
applied to the VA patient population estimates.”
Presently, there is nodiagnostic test forADsodiagnosis de-
pends on the recognition of acquired impairment in multiple
cognitive domains, including memory, language, visuospatial
ability, executive function, and mood, that is severe enough to
interferewith social or occupational functioning.A prodromal
phase is recognized called mild cognitive impairment where
cognitive decline is present but not yet severe enough to cause
functional impairment. Pathologic confirmation of AD relies
on the presence of two features: amyloid plaques composed
of extracellular aggregates of the protein amyloid and neurofi-
brillary tangles comprising intraneuronal deposits of the pro-
tein tau. Current thought hypothesizes that neuronal death in
AD is related to toxic effects of amyloid. Genetic factors
contributing to AD include mutations on a small number of
genes that cause AD primarily in young-onset patients and
riskgenes such as theE4allele of theApoEgene that increases
the risk of AD by three to 10 times [3]. Although age is the
strongest risk factor for AD, modifiable risk factors have
been identified that include head trauma, less physical activity,
and cardiovascular risk factors such as hypertension, stroke,
diabetes, cigarette smoking, and high cholesterol [3].Fig. 2. Formation of TaClo from TCE and PERC. 1-trichloromethyl-
1,2,3,4-tetrahydro-b-carboline (TaClo) forms in the presence of tryptamine
after cytochrome P450 2E1 (CYP2E1)-mediated oxidation of trichloroeth-
ylene (TCE) or tetrachloroethylene (perchloroethylene, PERC).2.1. Pesticides
The association of chemical exposures and AD is not as
well studied as other environmental risk factors, and results
are often inconsistent. Occupational exposure to pesticides
compared with unexposed was associated with a relative
risk of developing AD in men of 2.29 (95% confidence inter-
val [CI]5 1.02–5.630) in a cohort study of 1500 elderly par-ticipants living in southwest France. No association was
found in women, probably because of pesticide application
tasks being performed almost exclusively by men [4]. The
Cache County, Utah, study also assessed occupational expo-
sure to pesticides in general but added questions regarding
exposure to specific compounds including organophosphates
and organochlorines. More than 3000 participants free from
dementia at baseline received follow-up cognitive screening
at 3, 7, and 10 years; those with positive screens were exam-
ined for dementia. After adjustment for age, sex, education,
baseline cognitive function, and apolipoprotein e4 (APOE)
genotype the hazard ratio for developing AD was 1.42
(95% CI 1.06–1.91) for any pesticide exposure, 1.53 (95%
CI 1.05–2.23) for organophosphates, and 1.49 (95% CI
0.99–2.24) for organochlorines [5]. In another study of
more than 17,000 patients living in southern Spain, AD cases
were identified from computerized hospital records. The prev-
alence of AD was twice as high in those living in areas with
high pesticide exposure comparedwith areas of low exposure,
and this effect remained significant after adjustment [6].
Owing to their persistence in the environment, organochlo-
rines can be measured in body tissue years after exposure.
Several studies have examined the association of serum levels
of organochlorines and AD. In a recent case-control study
from North India, mean levels of nine detected organochlo-
rines were higher in 70 AD cases compared with 75 controls.
Levels of three of these—B-HCH, dieldrin, and pp’-DDE—
were significantly higher in cases [7]. Serum levels of
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subjects compared with 50 Parkinson’s disease patients and
43 normal controls in another case-control study [8].
Despite the fact that herbicides were used extensively dur-
ing the Vietnam War, there are few studies of pesticide expo-
sure and cognitive impairment or AD among veterans or
active-duty military. More than 11 million gallons of the her-
bicide Agent Orange were sprayed over Vietnam between
1962 and 1971 to clear vegetation that could be used as cover
by the enemy and to destroy food crops. The two constituents
of Agent Orange—2,4-dichlorophenoxyacetic acid (2,4-D)
and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)—as well as
a 2,4,5-T contaminant, dioxin, have long been implicated in
adverse health outcomes. The Air Force Health Study begin-
ning in 1982 examined the association of Agent Orange expo-
sure and health outcomes, including cognitive impairment.
The cohort consisted of Air Force personnel exposed to Agent
Orange through involvement in Operation Ranch Hand, the
defoliant initiative in Vietnam, and an unexposed comparison
group comprising personnel serving in other areas of South-
east Asia where Agent Orange was not used. Although global
cognitive impairment among those with higher dioxin levels
was not evident, there were lower scores on immediate and
delayed recall as well as visuospatial memory in this group
relative to the nonexposed comparison group. Differences
were statistically significant, but small and of uncertain clin-
ical significance [9]. Results were similar in the Vietnam
Experience Study, in which neuropsychological performance
was examined inveterans serving in Vietnam and veterans not
serving in Vietnam. Overall neuropsychological functioning
was similar between the two groups. AlthoughVietnam veter-
ans had statistically significant lower scores on some tests of
visual memory, visuospatial function, and abstract thinking,
differences were small and of doubtful clinical relevance
[10]. Last, another study found no association between an
objective measure of Agent Orange exposure based on loca-
tion of service and neuropsychological test scores [11]. For
all of these studies, follow-up examinations are needed to
assess these subjects later in life when cognitive problems
typically become evident.
Supporting the need for additional studies is a recently
conducted independent scientific review of Agent Orange
and AD by the Institute of Medicine, National Academy of
Sciences. The committee concluded that there was inade-
quate or insufficient evidence of an association between
Agent Orange exposure and AD [12].
2.2. Solvents
Exposure to organic solvents and AD risk is less well
studied. In one case-control study using incident cases of
AD, exposure to one or more solvent groups was associated
with an adjusted odds ratio (OR) of 2.3 (95% CI 1.1–4.7)
[13]. However, occupational exposure to solvents was not
associated with AD in a meta-analysis analyzing 11 case
control studies [14].2.3. Metals
The role of metals in AD has been considered since
aluminum was found in high concentrations in brain regions
with many neurofibrillary tangles from AD patients by
Crapper and others in the early 1970s [15]. This was fol-
lowed by the seminal work of Perl and Brody who found
aluminum deposits in neurons bearing neurofibrillary tan-
gles in the brains of AD patients, whereas no aluminum
was found in healthy neurons [16]. Aluminum neurotoxicity
has been demonstrated in animal models. Rats exposed to
low-level aluminum ingestion develop severe cognitive
impairment in old age, and aluminum accumulates in neu-
rons of the hippocampal formation [17]. Epidemiological
studies examining the association of aluminum exposure in
water and diet have been mixed [18]. High aluminum con-
tent in water was associated with higher risk for cognitive
decline and dementia in the prospective, population-based
Personnes Agees QUID study [19]. Tea in particular has
high levels of aluminum; however, several studies have
shown no association of tea consumption with AD [20].
Similarly, another study examining the association of
aluminum-containing antacids found no association [21].
Although the role of aluminum in the etiology of AD re-
mains unsettled, experimental evidence and observational
studies suggest an association between aluminum and AD
exists.
Interest in the role of transition metals in the etiology of
AD arises from the knowledge that excessive accumulations
of copper, zinc, and iron can lead to increased oxidative
stress and cytotoxicity. Some reports suggest these metals
are concentrated in and around amyloid plaques in AD and
may increase aggregation of amyloid [20,22]. However,
many studies do not support these findings. In particular, a
recent meta-analysis critically evaluated studies using
accepted quantitative techniques to assess levels of copper,
iron, and zinc in AD brains compared with similarly aged
controls and found that levels of these metals were not
elevated in AD brains. In view of these findings, the authors
suggested that the hypothesis that oxidative injury in AD is
related to transition metal excess should be reconsidered
[23].
Lead has been linked to several adverse health outcomes,
including cognitive impairment in children and adults,
although studies examining the association of lead exposure
with AD are few. Lead levels in the blood represent a mea-
sure of acute effects of recent lead exposure, whereas bone
levels represent cumulative lead burden over years [24].
For example, bone lead but not blood lead has been associ-
ated with cognitive decline in a nonoccupational cohort of
participants in the Veterans Affairs Normative Aging Study
with the visuospatial/visuomotor domain being the most
severely affected [25], suggesting that low-level cumulative
exposure impairs cognitive function, and visuospatial func-
tion in particular. Interestingly, the susceptibility to effects
on cognitive function related to cumulative lead exposure
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APOE gene is a firmly established risk factor for AD. Pres-
ence of at least one E4 allele compared with not having E4
was associated with a worsening of the adverse effect of
bone lead on neurobehavioral test scores among participants
occupationally exposed to lead [26].
2.4. TBI
Individuals with traumatic brain injury (TBI) are at
higher risk of dementia [27]. As discussed previously for
PD, the VA has recently determined a secondary service
connection for dementias of the following types: presenile
dementia of the Alzheimer type, frontotemporal dementia,
and dementia with Lewy bodies, if manifest within 15 years
after moderate or severe TBI (Federal Register 2013-29,911,
38 CFR Part 3, Docket ID: VA-2012-VBA-0029, pages
76196-76209.)3. Parkinson’s disease
PD is a chronic, progressive neurodegenerative disease of
aging characterized clinically by the classical motor signs of
parkinsonism (resting tremor, bradykinesia, cogwheel rigid-
ity, postural reflex impairment) and a variable constellation
of associated features including autonomic, sensory, cogni-
tive, and psychiatric changes. These clinical features corre-
spond to the anatomic distribution of pathologic changes,
consisting of neuronal degeneration and commonly aggrega-
tion of the protein alpha-synuclein in specific neuronal pop-
ulations, including the substantia nigra, locus ceruleus, other
brainstem and cortical regions, and the peripheral autonomic
nervous system. A prodromal period lasting many years pre-
cedes the onset of motor parkinsonism in many, if not all,
cases. Prodromal features preceding motor parkinsonism
may include constipation, hyposmia, rapid eye movement
sleep behavior disorder, reduced heart rate variability, anxi-
ety and depression.
As many as 1.5 million people in the United States
currently suffer from the disease, with an estimated 70,000
newly diagnosed cases per year. Men are more commonly
affected. Incidence increases with age, and onset before
age 50 is uncommon. The official number of individuals
with PD currently treated in the VA is not available. Howev-
er, an informal estimate is approximately 80,000 PD patients
(http://www.parkinsons.va.gov). These estimates do not
include veterans receiving care from other providers.
3.1. Genetics
Parkinsonism can be caused by genetic mutations, but
these inherited forms make up a small proportion of disease.
Studies in World War II veteran twins and other twin popu-
lations found low concordance for PD, suggesting that envi-
ronmental causes are important for most people with PD
[28,29]. The most common genetic form of PD, PARK8,
causes about 2% of PD cases in the United States [30]. Pene-trance is incomplete in this dominantly inherited parkin-
sonism, and environmental or other genetic factors
determine whether PD will occur in carriers. Common ge-
netic variation also causes small increases in PD risk, typi-
cally 10%–15% [31]. The interaction of environmental
exposure and genetic variation (gene–environment interac-
tion) likely cause most cases of PD.3.2. Environmental modifiers
Interest in environmental causes of PD was sparked when
the chemical MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) (Fig. 1) was identified as the cause of
human parkinsonism clinically similar to PD [32]. Labora-
tory studies showed that MPTP enters the brain via the large
neutral amino acid transporter and is metabolized to a reac-
tive compound that specifically blocks mitochondrial com-
plex I, causing experimental parkinsonism [33–37]. These
observations provided biologic plausibility to the
hypothesis that environmental chemical exposure could
cause PD.3.3. Pesticides
Because MPTP resembles the herbicide paraquat (1,10-
dimethyl-4,40-bypyridinium dichloride) (Fig. 1) structurally
and the insecticide rotenone functionally and because
several ecologic studies suggested a rural preponderance
of PD, pesticides and other factors associated with the rural
environment were among the earliest chemical exposures
investigated [38]. An association between pesticide expo-
sure and PD has been confirmed based on more than 80 pop-
ulations studied [39]. The term pesticide includes herbicides,
insecticides, fungicides, and rodenticides, and represents
hundreds of chemicals with widely different structures and
biologic effects. Identifying specific chemicals is important
to understanding disease pathogenesis, yet few studies inves-
tigated specific compounds. Studies that exist suggest that,
in addition to direct toxic effects pesticides may have, sus-
ceptibility to PD from pesticides may occur through modifi-
cation of genes for detoxifying enzymes. An example is a
recent study indicating that alterations in neuronal aldehyde
dehydrogenase enzymes are associated with increased risk
for development of PD [40].
The pesticide most frequently associated with PD is para-
quat, a commonly used herbicide with a structure similar to
MPTP [39]. Occupational paraquat exposure is associated
with more than double the risk of PD, and even “passive”
exposure through having a residence near treated fields can
increase risk, particularly when combined with the fungicide
maneb [41–43]. Persons with an inactive variant of the gene
encoding the detoxifying enzyme glutathione-S-transferase
T1 have an 11 times greater risk of PDwhen exposed to para-
quat than do thosewith a functional version of this gene [44].
In laboratory studies, paraquat causes increased production
of reactive oxygen species, alpha-synuclein aggregation,
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as a defoliant in military operations.
A second herbicide, the organochlorine 2, 4-
dichlorophenoxyacetic acid (2,4-D), was also associated
with more than double the risk of PD in one study [41] but
not others [49,50]. 2,4-D is a component of Agent Orange, a
tactical herbicide mixture used in Vietnam and recently deter-
mined to be a presumptive cause for PD in military veterans
[51]. The organochlorine dieldrin was shown to be elevated
in brains and serum of PD cases [52–54]. In the laboratory,
dieldrin causes alpha-synuclein fibrillary aggregation, depletes
dopamine, and causes oxidative stress. Other organochlorine
pesticides found at higher levels in brain or serum of PD cases
are lindane and beta-hexachlorocyclohexane [8,52], but these
compounds have not been associated with increased risk in
epidemiologic studies and specific military uses have not
been reported. Organochlorine toxicity may be greater in
persons with genetically determined low activity of
metabolizing enzymes, including ABCB1 and cytochrome
P450 2D6 [55,56]. Occupational exposure to permethrin, an
insecticide that blocks mitochondrial complex I and causes
oxidative stress, tripled the risk of PD in one study [41], but
the effect was less marked in another [57]. Animal studies of
permethrin indicate that exposure to permethrin upregulated
the vesicular monoamine transporter and the dopamine trans-
porter (DAT) as well as enhancing physical activity [58,59].
Because the metabolic product of MPTP metabolism
(MPP1) uses DAT to gain entry to dopaminergic neurons,
permethrin may enhance risk in environments where other
chemicals capable of entry through the DAT exist. Military
use of permethrin- or lindane-permeated uniforms and equip-
ment is common where malaria is endemic (http://www.
publichealth.va.gov/exposures/gulfwar/pesticides.asp). A
recent study concluded “that wearing permethrin-treated
clothing does increase absorbed, internal dose levels of
permethrin above population levels and is significantly related
to wear-time duration” [60]. Permethrin is considered safe and
protective in military use but is used with caution in specific
military subpopulations (http://phc.amedd.army.mil/topics/
healthyliving/wh/Pages/Women’sHealthPortal-Pregnancy.
aspx) [61]. Organophosphate insecticides act as cholines-
terase inhibitors, and are commonly used to control insect
disease vectors and pests. With repeated exposure, noncho-
linergic effects including disrupted axonal transport, neuro-
trophin function, mitochondrial complex I inhibition, and
oxidative stress may occur [62]. Exposure to methylpara-
thion [57] and chlorpyrifos [63] has been associated with
increased PD risk, but evidence is weak. Military exposure
to cholinesterase inhibitor pesticides for pest control or
chemical warfare and concurrent prophylaxis with pyrido-
stigmine has been proposed, but not proven, to contribute
to the syndrome of neurological and somatic symptoms
constituting the Gulf War Syndrome [62,64]. Other
pesticides blocking mitochondrial complex I, including
rotenone, also more than double the risk of PD. Inferred
residential exposure to the dithiocarbamate fungicidesmaneb, ziram, and zineb was associated with increased PD
risk in studies in the California Central Valley and adverse
effects may increase when combined with paraquat
[42,43,63]. These chemicals cause oxidative stress and
proteasomal dysfunction in experimental models, along
with injury to dopaminergic neurons [65]. Apart from
tactical use of pesticides, pesticides are used on bases or in
combat settings to control insects and plant overgrowth.3.4. Solvents
Occupational exposure to chlorinated solvents is also
associated with an increased risk of PD [66,67]. In a study
of World War II veteran twins, PD risk was more than six
times greater in the twin exposed to trichloroethylene,
TCE, and nearly significant increases were noted for
perchloroethylene (PERC; OR: 10.5, CI: 0.97-113), and
carbon tetrachloride (OR: 2.3, 95%CI: 0.9-6.1) [67] (Fig. 2).
TCE causes experimental parkinsonism in rats, produc-
ing reactive microglia, mitochondrial complex I inhibition,
oxidative stress, alpha-synuclein aggregation, and degenera-
tion of dopaminergic neurons. These chemicals are
commonly used in military and civilian settings as cleaners,
degreasers, and, in the past, skin disinfectants (http://www.
publichealth.va.gov/exposures/solvents/index.asp). These
solvents are environmentally persistent, and nonoccupa-
tional exposure may occur. For example, residential drinking
water systems at Camp Lejeune were contaminated with
chemicals, including PERC and TCE, between 1957 and
1985. To date, no adverse health effects have been associated
with this exposure [68] (http://www.publichealth.va.gov/
exposures/camp-lejeune/research.asp).3.5. Polychlorinated biphenyls
Evidence supporting a relationship between polychlori-
nated biphenyl (PCB) exposure and PD is inconsistent.
Women, but not men, occupationally exposed to PCBs
were more likely to die from PD [69], and women with
higher serum PCB levels were more likely to show imaging
evidence of reduced striatal dopamine transporter density
[70]. In postmortem studies, PCBs were higher in striatum
of PD cases than controls [71] However, in a prospective
study of Finnish workers, serum PCB levels were not higher
in workers who developed PD [72]. In animal models, PCB
exposure is associated with relatively selective, persistent,
reduction of dopamine, primarily affecting caudate, puta-
men, substantia nigra, and olfactory tract [73–76]. PCBs
persist in soil, water, and air, and tend to concentrate in
animals higher on the food chain. Dietary PCB intake has
been suggested as a cause of excess of PD in Greenland
[77]. PCBs were used extensively as coolants and lubricants
before a 1977 ban. Veterans whoworked on repair and main-
tenance of transformers, capacitors, and conduits before
1977 may have been exposed during military service
(http://www.publichealth.va.gov/exposures/pcb/index.asp).
C.M. Tanner et al. / Alzheimer’s & Dementia 10 (2014) S213-S225S2183.6. Other chemical exposures
Exposure to various metals, including manganese, iron,
and lead, has long been suggested to increase risk of PD,
based on experimental in vitro and in vivo studies, but human
evidence remains inconclusive [78–80].3.7. Particulate matter
Ambient total suspended particles from traffic have been
associated with an increased risk of PD [81]. Postmortem
comparison of brains from persons living in high and low
air pollution environments found ultrafine particulate matter
in the olfactory bulbs and immunoreactivity to beta amyloid
bA42 and/or alpha-synuclein in neurons, glial cells, and/or
blood vessels of those living in high, but not low, pollution
areas [82], and pollution-induced inflammatory brain mech-
anisms, suggesting that air pollution may be involved in the
development of PE and/or dementia. Veterans deployed to
polluted or dusty environments, such as the Persian Gulf
or Afghanistan, may be at risk for particulate matter expo-
sure, although to date increased mortality from PD has not
been observed [83] (http://www.publichealth.va.gov/
exposures/sand-dust-particulates/index.asp).3.8. TBI
Mild to moderate head injury, typically occurring decades
before PD onset, has been associated with increased risk of
PD in the majority of published studies [84] and risk increases
with the number of injuries [85–88]. There is evidence for
gene–environment interaction. PD risk is tripled in those
with a long Rep1 variant in the alpha-synuclein gene (OR
3.5, 95% CI 1.4–9.2, p-interaction 0.02), and age at disease
onset is nearly 5 years earlier in those with both head injury
and the gene variant [89]. TBI can cause disruption of blood
brain barrier, increasing central nervous system passage of
toxicants, can trigger inflammatory processes, interfere with
axonal transport, and induce aggregation of alpha-synuclein
and tau proteins, all processes that may ultimately lead to
neurodegenerative changes [90]. TBI may occur during mili-
tary service as the result of blast injuries, vehicle crashes, falls,
or other injuries. About 90% of head injuries during military
service are mild (http://www.publichealth.va.gov/exposures/
traumatic-brain-injury.asp). An estimated 285,000 Iraq and
Afghanistan veterans have been diagnosed with TBI as of
2008. The VA has published a new regulation, effective in
early 2014, providing for the consideration of PD and certain
dementing disorders because service-related disabilities in
veterans with moderate to severe service-related TBI (Federal
Register 2013-29,911, 38 CFR Part 3, Docket ID: VA-2012-
VBA-0029, pages 76196-76209.)3.9. Other modifiable risk factors
Although the focus of this review is on military-
associated chemical exposures, it is important to mentionthat many other factors have been associated with PD,
notably behavioral and lifestyle factors [91]. Those of
possible military relevance are mentioned here. A consistent
inverse association between tobacco use and PD was first
noted in the VA population [92,93] and subsequently
replicated in nearly every population studied worldwide
[94,95], including World War II veteran male twin pairs
discordant for PD [96], suggesting that some component
of tobacco, possibly nicotine, may protect against the devel-
opment of PD [97]. Caffeine use has also been inversely
associated with PD in several populations, especially in
men [98,99]. Preliminary reports suggest that physical
activity and certain dietary factors may lower PD risk
[100,101], whereas shift work may increase risk [102]. Pris-
oner of war status has been associated with increased PD risk
[103,104], but this is controversial [105]. Because PD likely
is determined by the combination of risk and protective fac-
tors plus genetic predisposition, awareness of these addi-
tional determinants can be important in planning
interventions for disease prevention as well as investigating
etiology.4. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly progres-
sive neurodegenerative disorder of motor neurons that typi-
cally results in death from respiratory failure within 3 years
of diagnosis. Although primary symptoms result from
degeneration of upper and lower motor neurons, ALS is a
multisystem disorder that widely affects non-motor neurons.
At least half of affected individuals manifest some degree of
executive dysfunction and other cognitive impairment, and
14% have frank frontotemporal dementia (FTD) [106].
ALS is clinically and pathologically pleiotropic and consti-
tutes a syndrome of diseases with likely diverse etiology
[107]. Incidence increases from 2/100,000 at age 50 to 15/
100,000 by age 75 [108,109]. Rates are similar in Europe,
North America, and Japan, but may be lower in China
[110], possibly reflecting its relatively recent industrializa-
tion. Increasing incidence over time could also implicate
environmental factors related to industrialization. This is
supported by several recent studies. Fang et al. found a
30% increased incidence from 1991 to 2005 in Sweden
[108], and Murphy et al. observed a doubling of incidence
in New Zealand from 1985 to 2006 [111]. Other recent
studies found birth cohort components suggesting the intro-
duction of an environmental risk factor during the early part
of the 20th century [112,113]. Incidence in men is 30%–50%
greater than in women, a difference that has narrowed in
more recent studies, possibly reflecting increasing
similarity of environmental risk factor exposures
[109,112,113].
Approximately 90% of ALS is sporadic and 10% famil-
ial, although this designation may result in substantial
misclassification [114]. A genetic basis has been identified
for approximately 60% of familial cases and 10% of
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include SOD1 (Cu/Zn superoxide dismutase), FUS (fused
in sarcoma), and TARDBP (TDP-43). A recently discovered
noncoding expansion of a hexanucleotide sequence in
C9orf72 is the most common genetic cause of both familial
(w40%) and sporadic (w6%) ALS, and is also a primary
cause of frontotemporal dementia [116]. ALS etiopathologic
processes involve oxidative and nitrative damage, microglial
activation/inflammation, mitochondrial dysfunction, protein
aggregation (e.g., TDP-43), impaired axonal transport,
apoptosis, growth factor alterations, glutamate excitotoxic-
ity, and dysregulated RNA metabolism (reviewed by Roth-
stein [117]). Importantly, different risk factors may affect
disease initiation and propagation.4.1. b-N-Methylamino-L-alanine (BMAA)
The environmental hypothesis of ALS derives in part
from the observation 60 years ago that rates of ALS were
100-fold higher among the indigenous Chamorro people of
the south Pacific island of Guam [118]. During the ensuing
decades, there has been a dramatic decline in incidence,
strongly suggesting a reduction in exposure to one or more
causative environmental agents, possibly of a chemical or in-
fectious nature. BMAA is a non-protein amino acid pro-
duced by ubiquitous cyanobacteria, which has been
suspected as the environmental agent responsible for the
Guamanian ALS cluster. BMAA is a glutamate receptor
agonist that depletes glutathione and may enhance protein
aggregation [119]. The BMAA hypothesis was initially
based on the observation that it was present in flour made
from the seed of the cycad plant Cycas micronesica, which
was a dietary staple of the Guamanian Chamorro people
[120]. Although its concentration in cycad flour is too low
to cause toxicity [121], BMAA is bioconcentrated by fruit
bats (flying foxes) and other animals whose consumption
may result in very large exposures [122,123]. The
hypothesis gained support when BMAA was found in
brains of Chamorros who died from ALS, but was not
detected in normal control brains [124]. In a larger follow-
up study, this same research group detected BMAA in
protein-bound fractions of brain tissue from U.S. patients
with sporadic ALS or AD, but not in normal controls or in
Huntington’s disease [125]. However, other investigators us-
ing different analytic methods failed to detect BMAA in
brain from Chamorros with ALS or patients with AD, cast-
ing doubt on the association [126,127].
Of particular relevance to the putative ALS cluster in
Gulf War veterans (see the following section), desert
dust in Qatar was found to contain cyanobacteria and asso-
ciated neurotoxins including BMAA and its isomer 2,4 di-
aminobutyric acid. The authors propose that physical
disturbance of the soil, such as through seasonal rains
and/or vehicular traffic, could aerosolize cyanotoxins
and lead to substantial inhalation [128]. A possible rela-
tionship to BMAA has also been proposed in a NewHampshire cluster where a 10- to 25-fold higher than ex-
pected incidence of ALS occurred among residents living
near a small lake with frequent cyanobacterial blooms
[129].
Motor neurons are particularly sensitive to BMAA
toxicity [130], and animal models manifest some of the mo-
tor deficits seen in ALS as well as evidence of mitochondrial
disruption and increases in TDP-43 protein [131,132].
However, other animal models do not replicate ALS
pathology, and BMAA toxicity is very low in cellular
models [118]. Although relatively high concentrations of
BMAA are required to cause toxicity in cellular and animal
models, synergism with other toxicants such as methylmer-
cury has been reported [133].4.2. Gulf war
Several studies assessed the rate of ALS associated with
military service in the 1991 Gulf War. This research was
spurred by reports of a large number of young service mem-
bers with ALS. Haley identified cases of ALS between
1991 and 1998 from military registries and a publicity
campaign, and found 17 affected Gulf War veterans
younger than age 45. The observed incidence equaled the
expected incidence from 1991 to 1994, but increased to
two- or three-fold the expected incidence after 1995
[134]. Horner et al attempted to ascertain all ALS cases
by the end of 1999 among individuals on active duty
August 1990 through July 1991. Personnel deployed to
the Gulf Region were considered “exposed,” and those
not deployed to the Gulf were considered “unexposed.”
They identified 107 cases among 2.5 million personnel,
and found a doubling of risk associated with deployment
to the Gulf (relative risk [RR] 1.9, 95%CI 1.3–2.8); risk
was highest for deployed Air Force personnel (RR 2.7,
95%CI 1.2–5.8) [135]. In contrast, a study of Gulf War vet-
eran mortality through 2004 found no excess frequency of
ALS [83]. Horner et al. suggest that the increased rate of
ALS was a time-limited outbreak that peaked in 1996 and
declined thereafter [136].
No specific environmental factors have been linked to
Gulf War service, but Miranda et al. used a geographic infor-
mation system analysis to identify specific service locations
within the Gulf associated with subsequent ALS [137]. Risk
was higher in proximity to chemical weapons facilities at
Khamisiyah, Iraq, as well as several other specific locations
where unknown environmental exposures may have
occurred. However, in the 1.2 million member American
Cancer Society Cancer Prevention Study II prospective
cohort, ALS mortality was increased with any military ser-
vice, and not specifically Gulf War service [138], consistent
with a common environmental exposure associated with
military service in general. Based on the epidemiologic
data and a summary report by the Institute of Medicine
[139], the VA presumes ALS diagnosed in all veterans is
related to their service, irrespective of period of service.
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The neurotoxic properties of lead have been recognized
for centuries. Lead is a pro-oxidant, stimulates protein ag-
gregation, disrupts glutamatergic signaling, and alters
neuronal growth factors [140]. It is of particular interest to
the military because of the possibility of exposure through
a range of activities including weapons emissions and lead
paint. Lead is one of the most extensively studied environ-
mental risk factors in ALS, with reported associations as
early as 1850 [141]. Numerous studies of widely varying
quality have been conducted, most of which found at least
a doubling of risk of ALS (reviewed elsewhere [142,143]).
Bone lead reflects cumulative exposures (trabecular bone
half-life 3–5 years, cortical bone half-life 15–25 years)
[144], and it avoids possible recall bias of historical studies.
Kamel et al. found a dose-dependent increased risk of ALS
associated with both patellar and tibial lead, with a 2.3- to
3.6-fold increase for each doubling of bone lead [145]. In
a large population of U.S. military veterans, the same group
assessed blood lead levels while adjusting analyses for mea-
sures of bone turnover. A doubling of blood lead was associ-
ated with a 1.9-fold adjusted risk of ALS [146].
Interestingly, a doubling of risk was also associated with a
polymorphism in the ALAD gene encoding the lead-
binding protein d-aminolevulinic acid dehydratase that en-
hances binding affinity [142].
4.4. Other metals
Like lead, mercury is a well-recognized neurotoxin, and a
mechanistic link to ALS is plausible. Case reports of ALS
after acute mercury intoxication have been described (re-
viewed in [143]). Though limited data exist, epidemiologic
studies provide little to no support of an association with
ALS [145,147–149]. However, mercury hastens the
development of the ALS phenotype in an SOD1 mutant
mouse model [150], and further research into possible ge-
netic and environmental interactions is warranted. Selenium
is both a pro- and antioxidant and is a potential neurotoxin
[151]. High levels of environmental seleniumwas associated
with a cluster of ALS [152], and ALS incidence was mark-
edly elevated in association with high selenium levels in
drinking water [153,154], but tissue-based studies have
been mostly negative [155,156].
4.5. Pesticides
At least a dozen studies have investigated associations of
pesticide exposure and ALS risk [148,149,157–162].
Although not all were statistically significant, every study
with at least five exposed subjects reported an increased risk
of ALS, with ORs ranging from 1.4 to 6.5. In addition,
other studies found an increased risk associated with
agricultural work [163–165]. McGuire et al. conducted a
high-quality population-based study of 174 incident cases
and 348 well-matched controls in Washington state [148]. In-dustrial hygienists (IH) unaware of disease status estimated
exposures by review of lifetime occupational history ques-
tionnaires. In men, ever-exposure to agricultural chemicals
(pesticides and fertilizers) was significantly associated with
ALS (OR 2.8, 95%CI 1.2–4.8), and risk was similarly
increased for exposure to insecticides. Importantly, a dose-
response relationship was seen, with an OR of 1.6 for low
exposure to pesticides (relative to no exposure) and 3.3 for
high exposure (P for trend 5 0.02). In the only prospective
cohort study of pesticides and ALS, self-reported regular
pesticide exposure at study baseline was not associated with
mortality from ALS (RR 1.1, 95%CI 0.8–1.4), although risk
was modestly elevated (RR 1.4, 95%CI 0.9–2.3) when sub-
jects with incomplete exposure data were excluded [160].
Only a single study assessed exposure to specific agents.
Kamel et al. [161] studied a large cohort of professional
pesticide applicators, a highly exposed population with
good recall of the specific chemicals they used. Forty-one
cases with ALS determined through death records were
compared with the 84,698 cohort members without ALS.
ALS risk tended toward significance for ever use of organo-
chlorine insecticides (OR 1.6, 95%CI 0.8–3.5), pyrethroids
(OR 1.4, 95%CI 0.6–3.4), herbicides (OR 1.6, 95%CI 0.7–
3.7), and fumigants (OR 1.8, 95%CI 0.8–3.9). Although no
specific agent was significantly associated, risk was consis-
tently elevated for individual organochlorine insecticides
including aldrin (OR 2.1, 95%CI 0.8–5.1), dieldrin (OR
2.6, 95%CI 0.9–7.3), DDT (OR 2.1, 95%CI 0.9–5.0), and
toxaphene (OR 2.0, 95%CI 0.8–4.9).
Two recent independent meta-analyses of studies of pes-
ticides and ALS both found summary risk ratios of 1.9 with
minimal between-study heterogeneity [141,161]. Thus, the
totality of epidemiologic evidence provides good support
for an association of pesticides and ALS. Military aspects
of pesticide use are discussed previously in the PD and
AD sections.4.6. Solvents
Solvent exposure can cause oxidative stress, mitochon-
drial toxicity and protein aggregation, and damage the cyto-
skeleton of long axons, resulting in a polyneuropathy [166].
Solvents are commonly used by military service members in
a wide variety of settings for purposes such as cleaning, de-
greasing, and painting, and some agents are common
groundwater contaminants. Numerous studies over several
decades have assessed the association of solvents and
ALS, with many finding an increased risk associated with
self-reported solvent exposures [157–159,165] and/or
occupations with likely exposure, such as carpenters,
painters, construction workers, or leather workers
[147,164,167]. However, others found no association with
solvents [149,162,168], and in the large prospective
American Cancer Society Cancer Prevention Study II
prospective cohort mortality study, risk was not increased
for those endorsing the use of chemicals/acids/solvents
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solvents as a general class, rather than specific agents. In
contrast, McGuire et al. assessed specific agents in their
Washington state case control study described previously
[148]. IH-determined risk was significantly elevated for sol-
vent classes including alcohols/ketones (OR 2.0, 95%CI
1.0–4.0) and degreasers (OR 1.9, 95%CI 1.1–3.3), and was
near-significant for benzene, toluene, or xylene. Specific
agents were also assessed by Fang et al. using IH review
of occupational histories [147]. Many solvent chemicals
were associated with ALS risk—predominantly in non-
smokers. These included acetone (OR 2.5, 95%CI 1.0–
6.3), aliphatic chlorinated hydrocarbons (OR 4.1, 95%CI
1.6–8.9), glycol ethers (OR 5.1, 95%CI 1.9–13.7), n-hexane
(OR 3.4, 95%CI 1.3–9.6), and xylene (OR 3.1, 95%CI 1.2–
8.1). The authors propose that smoking may reduce the
toxicity of these agents via induction of metabolic enzymes.4.7. Formaldehyde
Formaldehyde gasmay be emitted from plywood building
materials or from insulation, glues, or paints, and has been
identified as a cause of health complaints among deployed
personnel at bases in Iraq and Afghanistan. (http://phc.
amedd.army.mil/PHC%20Resource%20Library/Formaldeh
yde%20FS%2055-012-1011.pdf) Self-reported exposure to
formaldehyde at study baseline was associated with an
increased risk of subsequent ALS mortality in the prospec-
tive ACS-II study (RR 2.5, 95%CI 1.6–3.9), with a strong
dose-response relationship for years of use (P 5 .0004)
[160]. In a high-quality case control study that used IH esti-
mates of cumulative lifetime exposure, formaldehyde was
not associated with ALS, except in those with the very high-
est cumulative exposures. Risk was increased threefold in
those with greater than 60,000 lifetime hours of exposure
[147]. Possible toxic mechanisms include inhibition of su-
peroxide dismutase and mitochondrial damage [169].
Smoking has been associated with increased risk of ALS
in several rigorous studies [170–172], but others, including a
large prospective Swedish cohort [173] found no association
(reviewed in [174]). A meta-analysis that pooled results of
five large prospective cohorts found significantly increased
risk in both men and women smokers (RR 1.4, 95%CI
1.1–1.9), as well as a suggestion of a dose response, and
increased risk associated with initiating smoking at a
younger age [175]. Proposed mechanisms include oxidative
stress, combustion-generated formaldehyde, and effects on
vascular endothelial growth factor [160,176].4.8. Future directions
PD, AD, and ALS often have overlapping clinical syn-
dromes. Certain chemical exposures and TBI are associ-
ated with increased risk of any of the three disorders,
suggesting a common mechanism of injury among the
late-life neurodegenerative disorders. Phenotypic expres-sion after a chemical insult or TBI may be the result of
multiple factors, including genetically determined vulnera-
bilities and other beneficial or harmful environmental con-
ditions. Shared clinical features and risk profiles suggest
that screening for multiple neurodegenerative disorders
simultaneously may be the most efficient approach. In
some cases, preventive interventions may also be useful
for more than one of these neurodegenerative disorders.
Identification of risk factors and interventions in veteran
populations may ultimately lead to the development of
effective interventions to protect active military personnel
from future neurodegenerative disease.References
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